Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668757 | SCV000793407 | likely pathogenic | Bardet-Biedl syndrome 2 | 2017-08-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000806329 | SCV000946320 | pathogenic | Bardet-Biedl syndrome | 2023-08-11 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Ser605*) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is present in population databases (rs201063733, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with BBS2-related conditions (PMID: 25999675, 27659767). ClinVar contains an entry for this variant (Variation ID: 553335). |
Fulgent Genetics, |
RCV002507165 | SCV002811616 | pathogenic | Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 | 2021-12-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000668757 | SCV004214033 | pathogenic | Bardet-Biedl syndrome 2 | 2023-05-13 | criteria provided, single submitter | clinical testing | |
Department of Pediatrics, |
RCV000668757 | SCV004042815 | pathogenic | Bardet-Biedl syndrome 2 | no assertion criteria provided | clinical testing |